Lurbinectedin is a medication used in the treatment of certain types of cancer. To determine the frequency of lurbinectedin-induced nausea, we can refer to the provided sources.

According to the drug patent information on DrugPatentWatch, the prescribing information for lurbinectedin does list nausea as a potential side effect. However, the specific incidence rate of nausea is not mentioned [1].

A study published on PubMed titled "Lurbinectedin in relapsed small-cell lung cancer: results from a phase II single-agent trial" evaluated the safety and efficacy of lurbinectedin in patients with relapsed small-cell lung cancer. The study mentions that nausea was one of the most common adverse events observed, but it does not provide detailed information on the frequency or severity of nausea [2].

The Mayo Clinic's website provides information on the side effects of lurbinectedin. Nausea is listed as a common side effect, which means it occurs in a significant number of patients but may not affect everyone. However, the specific frequency of nausea is not mentioned [3].

Based on the available information, it can be concluded that nausea is a known side effect of lurbinectedin. However, the exact prevalence or frequency of lurbinectedin-induced nausea is not specified in the provided sources. It is important for patients to discuss any concerns or potential side effects with their healthcare provider, who can provide more personalized information and guidance.

Sources:
[1] DrugPatentWatch: Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] PubMed: Lurbinectedin in relapsed small-cell lung cancer: results from a phase II single-agent trial. Retrieved from https://pubmed.ncbi.nlm.nih.gov/35715960/
[3] Mayo Clinic: Lurbinectedin (Intravenous Route) - Side Effects. Retrieved from https://www.mayoclinic.org/drugs-supplements/lurbinectedin-intravenous-route/side-effects/drg-20490804?p=1